Datapoint: GSK Scores Full Approval for Jemperli

June 8

The FDA on June 6 granted full approval to GSK’s Jemperli (dostarlimab) for the treatment of mismatch repair-deficient (dMMR) recurring or advanced endometrial cancer, in combination with chemotherapy. The agency originally granted the immune checkpoint inhibitor accelerated approval in April 2021. For the treatment of endometrial cancer, Jemperli — which is administered as an intravenous infusion — currently holds covered or better status for 88% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/7/23